T. R. Minei

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma

P. Wen, T. Cloughesy, N. Butowski, 2021, Neuro-oncology advances.

Abstract 4979: Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors

I. Barshack, D. Harats, R. Shapira-Frommer, 2019, Immunology.

Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings

B. Monk, I. Barshack, R. Shapira-Frommer, 2019, Gynecologic Oncology.

Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.

M. Birrer, D. Harats, R. Penson, 2019, Journal of Clinical Oncology.